- Home
- ATLN vs CRDF Comparison
ATLN vs CRDF Comparison
Compare ATLN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLN
- CRDF
- Stock Information
- Founded
- ATLN 2014
- CRDF 1999
- Country
- ATLN United States
- CRDF United States
- Employees
- ATLN N/A
- CRDF N/A
- Industry
- ATLN
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATLN
- CRDF Health Care
- Exchange
- ATLN NYSE
- CRDF Nasdaq
- Market Cap
- ATLN 269.5M
- CRDF 240.2M
- IPO Year
- ATLN 2021
- CRDF N/A
- Fundamental
- Price
- ATLN $3.53
- CRDF $4.24
- Analyst Decision
- ATLN
- CRDF Strong Buy
- Analyst Count
- ATLN 0
- CRDF 3
- Target Price
- ATLN N/A
- CRDF $10.33
- AVG Volume (30 Days)
- ATLN 32.2K
- CRDF 1.0M
- Earning Date
- ATLN 01-01-0001
- CRDF 02-27-2025
- Dividend Yield
- ATLN N/A
- CRDF N/A
- EPS Growth
- ATLN N/A
- CRDF N/A
- EPS
- ATLN N/A
- CRDF N/A
- Revenue
- ATLN $429,260,149.00
- CRDF $688,000.00
- Revenue This Year
- ATLN N/A
- CRDF $25.03
- Revenue Next Year
- ATLN N/A
- CRDF N/A
- P/E Ratio
- ATLN N/A
- CRDF N/A
- Revenue Growth
- ATLN 5.50
- CRDF 49.57
- 52 Week Low
- ATLN $1.30
- CRDF $1.47
- 52 Week High
- ATLN $8.98
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- ATLN N/A
- CRDF 60.32
- Support Level
- ATLN N/A
- CRDF $3.78
- Resistance Level
- ATLN N/A
- CRDF $4.23
- Average True Range (ATR)
- ATLN 0.00
- CRDF 0.22
- MACD
- ATLN 0.00
- CRDF 0.06
- Stochastic Oscillator
- ATLN 0.00
- CRDF 88.93
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").